Results
The model showed that FeNO, was associated with lower total cost than SC (US $1333 vs US $1452 average cost per patient), and higher QALYs (0.93 vs. 0.92 average per patient); showing dominance. The probability that MS provides a more cost-effective use of resources compared with standard therapy exceeds 99% for all willingness to pay thresholds